-
Mashup Score: 8Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity | PNAS - 1 month(s) ago
Clinical trials in cancer are ideally built on a foundation of sound mechanistic rationale and well-validated drug activity in relevant disease mod…
Source: www.pnas.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Potential Role of Dose-Adjusted EPOCH-R in the Frontline Setting Among Patients With Aggressive B-Cell Lymphomas - 5 month(s) ago
Mark Roschewski, MD, shared expert insight on the possible role of dose-adjusted EPOCH-R as first-line treatment for patients with aggressive B-cell lymphomas.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/N0oJGYkgCw
-
-
Mashup Score: 5Potential Role of Dose-Adjusted EPOCH-R in the Frontline Setting Among Patients With Aggressive B-Cell Lymphomas - 5 month(s) ago
Mark Roschewski, MD, shared expert insight on the possible role of dose-adjusted EPOCH-R as first-line treatment for patients with aggressive B-cell lymphomas.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/N0oJGYkgCw
-
-
Mashup Score: 1ESH - European School of Haematology - 2 year(s) ago
7th Translational Research ConferenceLymphoid MalignanciesOctober 20-22, 2023 – Estoril, Portugal #ESHLYMPHOID2023 Chairs: Michael Hallek, Georg Lenz, Laurie Sehn, Louis Staudt REGISTRATION & ABSTRACT SUBMISSION ARE OPEN! ABOUT THE CONFERENCE: ESH Translational Research Conferences focus on leading-edge basic, clinical and therapeutic research and future perspectives.The presentation of…
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @ESHaematology: #ESHLYMPHOID2023 ONLY 2 WEEKS LEFT TO SUBMIT YOUR ABSTRACT! Proceed now ➡ https://t.co/H7msA3tCdI 🗓️ Oct. 20-22, 2023 in…
-
-
Mashup Score: 2Please wait whilst we redirect you - 2 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ErenVeziroglu: My latest work on AI methods for evaluating PET/CT images of lymphoma, online now https://t.co/UR7ePhPXhE We focus on me…
-
-
Mashup Score: 4Burkitt’s Lymphoma | NEJM - 2 year(s) ago
Review Article from The New England Journal of Medicine — Burkitt’s Lymphoma
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
Burkitt’s Lymphoma | NEJM https://t.co/V032Xx1ZzV Are you interested in reading about the history, biology, and treatment of this fascinating lymphoma?
-
-
Mashup Score: 0Hemato - 2 year(s) ago
Hemato, an international, peer-reviewed Open Access journal.
Source: www.mdpi.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Check out this themed issue highlighting contributions of @Hememachine Elaine Jaffe Classification of Lymphomas and Hematological Neoplasia in the Era of Genomic Research: A Themed Issue in Honor of Dr. Elaine S. Jaffe https://t.co/u4LKnk9dkS #mdpihemato via @MDPIOpenAccess
-
-
Mashup Score: 4Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma - 3 year(s) ago
Key Points. MCD-associated genetic lesions strongly promoted accumulation of B cells in splenic germinal centers (GCs) of unimmunized miceMice engineered to har
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Fascinating new paper by the Muppidi lab investigating the possible cell-of-origin for MCD/C5 DLBCL Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma https://t.co/67jIGZ2vVh
-
-
Mashup Score: 2Virtual Lymphoma Rounds: Washington, DC – March 22, 2022 - 3 year(s) ago
Time: 7:00 PM – 8:30 PM ET
Source: Lymphoma Research FoundationCategories: Hem/Oncs, Latest HeadlinesTweet-
Washington DC 2022 @lymphoma Rounds is less than a week away! Join me and other fellow physicians across the country on March 22 to learn more about the treatment of lymphoma – get more information and register at https://t.co/RygG9tPKGN.
-
-
Mashup Score: 11Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA - Nature Biotechnology - 3 year(s) ago
The sensitivity of circulating tumor DNA detection is improved by identifying sequences with two or more mutations.
Source: Nature BiotechnologyCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @AshAlizadeh: Delighted to share our new study https://t.co/o2QcGsVNGQ introducing PhasED-Seq out today @NatureBiotech.
-
Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity | PNAS https://t.co/Q9N9Ccd0lz Read the background story of how the VIPOR drugs were discovered to have synergy in LBCL.